Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple Myeloma
Pieter Sonneveld, MD, PhD, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.
Pieter Sonneveld, MD, PhD, professor of hematology and head of the Department of Hematology at Erasmus MC Cancer Institute in The Netherlands, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.
Sonneveld says that not only high-risk patients but all those who are transplant-eligible and newly diagnosed may potentially have a new standard of care in the future. The new standard will come from the combination of daratumumab (Darzalex) and bortezomib (Velcade) plus thalidomide (Thalomid; VTd), or the regimen of bortezomib, lenalidomide (Revlimid), dexamethasone (VRd), or other triple-drug combinations going to a 4-drug regimen, including daratumumab.
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
